CaldrionPrivate CreditSearchRequest financing

TransactionNAV lending

Project Keystone: NAV loan to a lower-middle-market buyout fund

A $40.0M NAV loan at 13% LTV that funded two value-creating add-on acquisitions for a fund in year nine, when its investors wouldn’t meet a capital call.

A closed Caldrion loan, shown under its project code name. The borrower and sponsor are not named. Terms are as of closing; returns are our underwriting targets, not realized results.

NAV loan · $40.0M · 13% LTV · S+650

At a glance

BorrowerA holding company (SPV) that owns the remaining portfolio of a 2017-vintage, $400M lower-middle-market buyout fund, with a guaranty from the fund
CollateralPledge of the SPV’s equity in 8 portfolio holding companies (NAV $310M), plus control of the accounts that receive distributions
Loan$40.0M delayed-draw term loan
Leverage12.9% LTV (13.9% on eligible NAV); covenant maximum 25%
Term36 months plus one 12-month extension
PricingS+650 (≈10.25%); 1.00% origination; 0.50% unused fee
Timeline6 weeks, mostly valuation work on all 8 companies

The situation

The fund was in year nine, after a two-year extension its investors approved, and exits had slowed. Two portfolio companies, a commercial HVAC services platform and a specialty insurance brokerage, had acquisitions under letter of intent needing $22M and $14M of equity.

The fund’s reserves were used up, and its investors wouldn’t fund a capital call. A continuation vehicle would have taken 6–9 months and would likely have priced below NAV. Without the follow-on money, both companies would have lost deals that increase their value.

Uses

Uses$M
HVAC platform add-on22.0
Brokerage add-on14.0
Interest reserve2.5
Fees and expenses1.5
Total40.0

Eligible NAV

PortfolioNAV
Top 3 companies$161M (52%)
Other 5 companies$149M
Less: NAV above the 25% single-company cap($22M)
Eligible NAV$288M

Structure

  • Proceeds can only fund value-creating follow-on investments, not distributions to the fund’s investors.
  • Cash sweep: 75% of net distributions go to Caldrion while LTV is above 10%, and 50% once it falls below 10%.
  • LTV ladder: above 20%, the sweep goes to 100%. Above 25%, the fund has 60 days to cure through new equity or an asset sale. Above 30%, it’s an event of default.
  • At least 6 companies must remain in the borrowing base, with no single company above 25% of eligible NAV.
  • The fund manager marks values quarterly. We can commission an independent valuation once a year and whenever a trigger is hit.
  • Our claim sits behind each portfolio company’s own debt, so underwriting uses equity values net of that debt and stress-tests every company’s capital structure.
  • The loan includes a key-person event, approval from the fund’s investor advisory committee, and a ban on new fund-level debt.

Risks and mitigants

RiskMitigant
Ranks behind portfolio-company debtNAV is already net of that debt; stress tests; 13% LTV
Manager’s valuations are stale or optimisticIndependent valuation rights; haircuts
Exits take longer36+12 month term; cash sweeps; 3 companies already in sale processes
Concentration25% single-company cap; minimum of 6 companies

Exit and returns, as underwritten

Three companies with combined NAV of about $130M are in or near sale processes, expected to close in 12–24 months. At a 75% sweep, the first two exits alone repay the loan. Target: about an 11% IRR. Our own private equity team gives us an edge in valuing these companies.

Downside

If NAV falls 40% to $186M, LTV is 21.5% and the sweep goes to 100%, with roughly 4.6x coverage remaining.

See all our transactions, the twelve loans compared and our criteria.

This case study is provided for information only. It is not an offer of securities or investment advice, and targeted results do not indicate future results.

Insights

More to read.

Investment perspective

Twelve loans: the common thread

Twelve closed Caldrion loans at a glance, the five ingredients they share, and the loans we pass on.

Caldrion Private Credit

Transaction

Project Meridian: pharma royalty monetization

A $30.0M loan against a 6% royalty on an approved orphan drug, which funded a biotech’s Phase 2 trial without dilutive equity or selling the royalty outright.

Caldrion Private Credit